WALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic MORF, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in a Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference…Read More
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference Morphic Holding NASDAQMORF
